First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: iRhythm Technologies: the setup is constructive — Quarterly Zio patch volume growth and average selling price trends - unit economics drive revenue trajectory
★ Analysts see FY2026 revenue reaching $881M — +17.9% growth in a single year.
Why Revenue Could Accelerate
1Quarterly Zio patch volume growth and average selling price trends - unit economics drive revenue trajectory
2Medicare and commercial reimbursement rate decisions - CMS coverage policies and private payer contract renewals significantly impact revenue per test
3Operating margin progression toward breakeven - investors closely track path to profitability given current -19.5% operating margins
4Competitive threats from Abbott, Medtronic, and BioTelemetry (Philips) in ambulatory cardiac monitoring space
5Clinical study results validating Zio superiority and expanding addressable indications beyond arrhythmia detection
growth - The stock attracts growth investors focused on healthcare innovation and market share expansion in a large addressable market…
Rising interest rates create moderate headwinds through multiple channels.
Watch on earnings: Medicare reimbursement rates for extended Holter monitoring (CPT codes 93241-93248) published in annual Physician Fee Schedule, Quarterly Zio patch shipment volumes and revenue per patch trends, Operating margin trajectory and quarterly cash burn rate relative to $200M+ estimated cash position.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $881M to $1.0B as quarterly zio patch volume growth and average selling price trends - unit economics drive revenue trajectory.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.